 |
| CASE REPORT |
|
|
|
| Ahead of print
publication |
Cefoperazone/sulbactam-induced hemolytic anemia
XM Sun1, LH Liu1, Q Wu2, HG Wang1
1 Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
2 Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
| Date of Submission | 09-Dec-2020 |
| Date of Decision | 13-Feb-2021 |
| Date of Acceptance | 31-Mar-2021 |
| Date of Web Publication | 13-Sep-2021 |
Correspondence Address:
HG Wang,
Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing
China
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/jpgm.JPGM_1335_20 PMID: 34528516
Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-old female patient, who had an operation on the biliary tract 3 months ago, was admitted to our hospital with an abdominal infection. After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. Cefoperazone/sulbactam was discontinued and replaced with meropenem. Subsequently the level of red blood cells, hemoglobin, and hematocrit returned to normal. Clinicians should pay attention to monitoring the possible adverse reactions during the use of cefoperazone/sulbactam and should be aware of the occurrence of DIHA, so as to give timely treatment.
Keywords: Adverse reactions, cefoperazone, drug-related side effects, hemolytic anemia, sulbactam
.
|
